Efficacy of motesanib diphosphate in non-small-cell lung cancer

Bibliography

• Nishida N, Yano H, Nishida T, et al. Angiogenesis in cancer. Vasc Health Risk Manag 2006;2(3):213-19
   PubMedGoogle Scholar
• Grossi F, Aita M. Bevacizumab and non-small-cell lung cancer: starving the enemy to survive. Expert Opin Biol Ther 2007;7(7):1107-19
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised Phase III trial(AVAiL). Ann Oncol 2010;21(9):1804-9
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phased 3 trial. Lancet 2014; doi:10.1016/S0140-6736(14)60845-X
   PubMedGoogle Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49
   PubMed Web of Science ®Google Scholar
• De Boer RH, Kotasek D, White S, et al. Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat 2012;135:241-52
   PubMed Web of Science ®Google Scholar
• Benjamin RS, Schoffski P, Hartmann JT, et al. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol 2011;68:69-77
   PubMed Web of Science ®Google Scholar
• Shilder RJ, Sill MW, Lankes HA, et al. A phase. II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol 2013;129:86-91
   PubMedGoogle Scholar
• Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42
   PubMed Web of Science ®Google Scholar
• Aita M, Fasola G, Defferrari C, et al. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2008;68(3):183-96
   PubMedGoogle Scholar
• Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(11):1835-42
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, Biesma B, Heigener D, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012;30(25):3084-92
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Hirsh V, Park K, et al. Monotherapy administration of sorafenib in patients with non-small cell lung cancer: phase III randomized, double-blind, placebo-controled MISSION trial. Ann Oncol 2012;23(Suppl 9):LBA33_PR
   Google Scholar
• Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010;28(1):49-55
   PubMed Web of Science ®Google Scholar
• Laurie SA, Solomon BJ, Seymour L, et al. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Cancer 2014;50(4):706-12
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012;30(17):2070-8
   PubMed Web of Science ®Google Scholar
• de Boer RH, Arrieta Ó, Yang CH, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011;29(8):1067-74
   PubMedGoogle Scholar
• Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11(7):619-26
   PubMed Web of Science ®Google Scholar
• Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11(7):619-26
   PubMed Web of Science ®Google Scholar
• Lee JS, Hirsh V, Park K, et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial(ZEPHYR). J Clin Oncol 2012;30(10):1114-21
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15(2):143-55
   PubMed Web of Science ®Google Scholar
• Hanna NH, Kaiser R, Sullivan RN, et al. Lume-Lung 2: a multicenter, randomized, double-blind phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 2013;31:8034
   Web of Science ®Google Scholar
• Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006;66:8715-21
   PubMed Web of Science ®Google Scholar
• Dietrich J, Wang D, Batchelor TT. Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. Expert Opin Investig Drugs 2009;18(10):1549-57
   PubMed Web of Science ®Google Scholar
• Heng DYC, Kollmannsberger C. Small molecules in oncology. Springer - Verlag Berlin Heidelberg; 2010
   Google Scholar
• Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62(16):4645-55
   PubMed Web of Science ®Google Scholar
• Roth GJ, Heckel A, Colbatzky F, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem 2009;52(14)):4466-80
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
   PubMed Web of Science ®Google Scholar
• Alevizakos M, Kaltsas S, Syrigos KN. The VEGF pathway in lung cancer. Cancer Chemother Pharmacol 2013;72:1169-81
   PubMed Web of Science ®Google Scholar
• Suzuki H, Watabe T, Kato M, et al. Roles of vascular endothelial growth factor receptor 3 signaling in differentiation of mouse embryonic stem cell-derived vascular progenitor cells into endothelial cells. Blood 2005;105(6):2372-9
   PubMedGoogle Scholar
• Imoto H, Osaki T, Taga S, et al. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998;115(5):1007-14
   PubMed Web of Science ®Google Scholar
• Zhan P, Wang J, Lv XJ, et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 2009;4(9):1094-103
   PubMed Web of Science ®Google Scholar
• Pietras K, Sjoblom T, Rubin K, et al. PDGF receptors as cancer drugs targets. Cancer Cell 2003;3:439-43
   PubMed Web of Science ®Google Scholar
• Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998;11(8):728-34
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005;13(3):205-20
   PubMedGoogle Scholar
• Cooper WA, Lam DC, O’Toole SA, Minna JD. Molecular biology of lung cancer. J Thorac Dis 2013;5(Suppl 5):S479-90
   PubMedGoogle Scholar
• Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012;22(3):436-45
   PubMed Web of Science ®Google Scholar
• Coxon A, Ziegler B, Kaufman S, et al. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Mol Cancer 2012;11:70-82
   PubMedGoogle Scholar
• Fujisaka Y, Yamada Y, Yamamoto N, et al. Phase I study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2010;66:935-43
   PubMedGoogle Scholar
• Li C, Kuchimanchi M, Hickman D, et al. In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans. Drug Metab Dispos 2009;37(7):1378-94
   PubMedGoogle Scholar
• Blumenschein GR Jr, Reckamp K, Stephenson GJ, et al. Phase Ib study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitunumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 2010;16:279-90
   PubMed Web of Science ®Google Scholar
• De Boer RH, Kotasek D, White S, et al. Phase Ib study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitunumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 2010;16:279-90
   PubMedGoogle Scholar
• Kotasek D, Tebutt N, Desai J, et al. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC Cancer 2011;11:313-25
   PubMedGoogle Scholar
• Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:2544-55
   PubMed Web of Science ®Google Scholar
• Herbst RS, O’Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743-50
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Kabbinavar F, Menon H, et al. A phase II, multi center, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 2011;22:2057-67
   PubMed Web of Science ®Google Scholar
• Bass MB, Davis MT, Kivman L, et al. Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small-cell lung cancer, and locally recurrent or advanced metastatic breast cancer. J Clin Oncol 2010;28(Suppl 15s):abstract 3037
   Google Scholar
• Bass MB, Sherman SI, Schlumberger MJ, et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 2010;95(11):5018-27
   PubMed Web of Science ®Google Scholar
• Shahneh FZ, Baradaran B, Zamani F, Aghebati-Maleki L. Tumor angiogenesis and anti-angiogenic therapies. Hum Antibodies 2013;22(1-2):15-19
   PubMedGoogle Scholar
• Scagliotti GV, Vynnychenko I, Park K, et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 2012;30:2829-36
   PubMed Web of Science ®Google Scholar
• Kubota K, Ichinose Y, Scagliotti G, et al. Phase. III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall –cell lung cancer (NSCLC): asian subgroup analysis. Ann Oncol 2014;25(2):529-36
   PubMed Web of Science ®Google Scholar
• International Clinical Trials Registry Platform, Search Portal. Available from: http://apps.who.int/trialsearch/trial.aspx?trialid=JPRN-JapicCTI-121887
   Google Scholar
• Tracy S, Mukohara T, Hansen M, et al. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004;64(20):7241-4
   PubMed Web of Science ®Google Scholar
• Pan F, Tian J, Zhang X, et al. Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation. J Cancer Res Clin Oncol 2011;137(9):1397-408
   PubMedGoogle Scholar
• Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther 2012;13:247-63
   PubMed Web of Science ®Google Scholar
• Crino’ L, Metro G. Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. Eur Respir Rev 2014;23(131):79-91
   PubMedGoogle Scholar
• Rosen LS, Lipton L, Price TJ, et al. The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC Cancer 2013;13:242-52
   PubMedGoogle Scholar
• Mok TSK, Hsia TC, Tsai CM, et al. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial. Asia Pac J Clin Oncol 2011;7(2):4-12
   PubMedGoogle Scholar
• Kawaguchi T, Matsumura A, Fukai S, et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol 2010;5(7):1001-10
   PubMedGoogle Scholar
• Ou SH, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009;4:1083-93
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373(9674):1525-31
   PubMed Web of Science ®Google Scholar
• Zhou W, Christiani DC. East meets West: ethnic differences in epidemiology and clinical behaviours of lung cancer between East Asians and Caucasians. Chin J Cancer 2011;30(5):287-92
   PubMedGoogle Scholar
• Sekine I, Yamamoto N, Nishio K, et al. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008;99(11):1757-62
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Troiani T, Bianco R, et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 2006;17(Suppl 7):vii109-14
   PubMedGoogle Scholar
• Claret L, Bruno R, Lu JF, et al. Exploratory modelling and simulation to support development of motesanib in Asian patients with non-small cell lung cancer based on MONET1 study results. Clin Pharmacol Ther 2014;95(4):446-51
   PubMedGoogle Scholar